Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.38 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.36 |
| ▸ | PPARG | P37231 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | IL6 | P05231 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 2/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31611960 | 0.86 | KMT2A (0.43) | PKMNR1H4LMNA | |
| SCHEMBL21617101 | 0.86 | KMT2A (0.43) | PKMNR1H4LMNA | |
| SCHEMBL28636905 | 0.82 | GPR52 (0.34) | HSD17B13GPR52PTGS2DHODH | |
| SCHEMBL21617002 | 0.80 | GPR52 (0.33) | PKMHSD17B13GPR52LMNAPTGS2 | |
| SCHEMBL21617254 | 0.80 | FGFR4 (0.38) | GPR52POLB | |
| SCHEMBL28618751 | 0.69 | KMT2A (0.39) | PTGS2 | |
| SCHEMBL22899612 | 0.67 | SMN1; SMN2 (0.38) | PKMLMNA | |
| SCHEMBL29486220 | 0.67 | SMN1; SMN2 (0.38) | PKMLMNA | |
| SCHEMBL21617159 | 0.66 | CNR2 (0.42) | POLB | |
| SCHEMBL21616999 | 0.66 | SMN1; SMN2 (0.36) | PKMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739073-B2 | Aryl-n-aryl derivatives for treating a RNA virus infection | ABIVAX (FR) | 2023-08-29 | — | — | US | disclosed |
| US-11739073-B2 | Aryl-n-aryl derivatives for treating a RNA virus infection | ABIVAX (FR) | 2023-08-29 | — | — | US | disclosed |
| US-11739073-B2 | Aryl-n-aryl derivatives for treating a RNA virus infection | ABIVAX (FR) | 2023-08-29 | — | — | US | disclosed |
| US-20210300871-A1 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2021-09-30 | — | — | US | disclosed |
| US-20210300871-A1 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2021-09-30 | — | — | US | disclosed |
| EP-3820848-A1 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2021-05-19 | — | — | EP | disclosed |
| WO-2020011811-A1 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2020-01-16 | — | — | WO | disclosed |
| WO-2020011811-A1 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | ABIVAX (FR) | 2020-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300871-A1 | ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | HAVCR2, CBR3, C1R | PKM 3365/4885HSD17B13 1530/4885GPR52 1054/4885 |
| US-11739073-B2 | Aryl-n-aryl derivatives for treating a RNA virus infection | HAVCR2, CBR3, C1R | PKM 3365/4885HSD17B13 1530/4885GPR52 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.